140 related articles for article (PubMed ID: 35178186)
1. Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells.
Guo M; He S; Cheng J; Li Y; Dong G; Sheng C
ACS Med Chem Lett; 2022 Feb; 13(2):298-303. PubMed ID: 35178186
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
Cheng J; Li Y; Wang X; Dong G; Sheng C
J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC).
Bao J; Chen Z; Li Y; Chen L; Wang W; Sheng C; Dong G
ACS Med Chem Lett; 2024 Jan; 15(1):29-35. PubMed ID: 38229750
[TBL] [Abstract][Full Text] [Related]
4. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel KRAS‒PDE
Chen L; Zhang J; Wang X; Li Y; Zhou L; Lu X; Dong G; Sheng C
Acta Pharm Sin B; 2022 Jan; 12(1):274-290. PubMed ID: 35127385
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
8. Structure-based development of PDEδ inhibitors.
Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
[TBL] [Abstract][Full Text] [Related]
9. Exploring binding modes of the selected inhibitors to phosphodiesterase delta by all-atom molecular dynamics simulations and free energy calculations.
Zhong H; Zhang YJ; Shan XB
J Biomol Struct Dyn; 2019 Jun; 37(9):2415-2429. PubMed ID: 30052144
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells.
Fan R; He S; Wang Y; Qiao J; Liu H; Galstyan L; Ghazaryan A; Cai H; Feng S; Ni P; Dong G; Li H
Am J Cancer Res; 2022; 12(3):1027-1041. PubMed ID: 35411249
[TBL] [Abstract][Full Text] [Related]
11. Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism.
Winzker M; Friese A; Koch U; Janning P; Ziegler S; Waldmann H
Angew Chem Int Ed Engl; 2020 Mar; 59(14):5595-5601. PubMed ID: 31829492
[TBL] [Abstract][Full Text] [Related]
12. Hydrophobic tagging of small molecules: an overview of the literature and future outlook.
Zhou Y; Zhou F; Xu S; Shi D; Ding D; Wang S; Poongavanam V; Tang K; Liu X; Zhan P
Expert Opin Drug Discov; 2024 Jul; 19(7):799-813. PubMed ID: 38825802
[TBL] [Abstract][Full Text] [Related]
13. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
14. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors.
Jiang Y; Zhuang C; Chen L; Lu J; Dong G; Miao Z; Zhang W; Li J; Sheng C
J Med Chem; 2017 Nov; 60(22):9400-9406. PubMed ID: 28929751
[TBL] [Abstract][Full Text] [Related]
15. Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of
Armijo ME; Escalona E; Peña D; Farias A; Morin V; Baumann M; Klebl BM; Pincheira R; Castro AF
Front Pharmacol; 2022; 13():912688. PubMed ID: 35814251
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation.
Xie S; Zhan F; Zhu J; Sun Y; Zhu H; Liu J; Chen J; Zhu Z; Yang DH; Chen ZS; Yao H; Xu J; Xu S
Angew Chem Int Ed Engl; 2023 Mar; 62(13):e202217246. PubMed ID: 36670545
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
[TBL] [Abstract][Full Text] [Related]
18. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
Peng X; Hu Z; Zeng L; Zhang M; Xu C; Lu B; Tao C; Chen W; Hou W; Cheng K; Bi H; Pan W; Chen J
Acta Pharm Sin B; 2024 Feb; 14(2):533-578. PubMed ID: 38322348
[TBL] [Abstract][Full Text] [Related]
19. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site.
Murarka S; Martín-Gago P; Schultz-Fademrecht C; Al Saabi A; Baumann M; Fansa EK; Ismail S; Nussbaumer P; Wittinghofer A; Waldmann H
Chemistry; 2017 May; 23(25):6083-6093. PubMed ID: 27809361
[TBL] [Abstract][Full Text] [Related]
20. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
Salmas RE; Mestanoglu M; Yurtsever M; Noskov SY; Durdagi S
Biophys J; 2015 Sep; 109(6):1163-8. PubMed ID: 26340817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
